Mustang Bio (NASDAQ:MBIO – Get Free Report) will likely be issuing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($140.00) per share for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 6:00 PM ET.
Mustang Bio Stock Up 1.3%
Shares of MBIO stock traded up $0.01 during mid-day trading on Monday, hitting $0.76. 40,984 shares of the company’s stock were exchanged, compared to its average volume of 135,799. Mustang Bio has a fifty-two week low of $0.53 and a fifty-two week high of $7.00. The stock has a 50-day simple moving average of $0.83 and a two-hundred day simple moving average of $1.04. The stock has a market cap of $5.79 million, a price-to-earnings ratio of -1.96 and a beta of 2.11.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Mustang Bio stock. DRW Securities LLC bought a new position in shares of Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 73,936 shares of the company’s stock, valued at approximately $73,000. DRW Securities LLC owned about 1.01% of Mustang Bio as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 9.95% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on Mustang Bio
Mustang Bio Company Profile
Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.
The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.
Featured Articles
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.
